Gross Profit Analysis: Comparing Vertex Pharmaceuticals Incorporated and Jazz Pharmaceuticals plc

Vertex vs. Jazz: A Decade of Gross Profit Growth

__timestampJazz Pharmaceuticals plcVertex Pharmaceuticals Incorporated
Wednesday, January 1, 20141055457000519428000
Thursday, January 1, 20151222277000906794000
Friday, January 1, 201613825870001491717000
Sunday, January 1, 201715085050002213533000
Monday, January 1, 201817693780002638058000
Tuesday, January 1, 201920338310003615063000
Wednesday, January 1, 202022146500005469383000
Friday, January 1, 202126534780006670200000
Saturday, January 1, 202231188570007850400000
Sunday, January 1, 202333986270008607000000
Monday, January 1, 20249489600000
Loading chart...

Data in motion

Gross Profit Growth: Vertex vs. Jazz Pharmaceuticals

In the competitive landscape of pharmaceuticals, gross profit is a key indicator of a company's financial health and operational efficiency. Over the past decade, Vertex Pharmaceuticals Incorporated and Jazz Pharmaceuticals plc have shown remarkable growth in this area. From 2014 to 2023, Vertex Pharmaceuticals has seen its gross profit surge by over 1,500%, starting from a modest 52 million in 2014 to an impressive 860 million in 2023. In contrast, Jazz Pharmaceuticals has experienced a steady growth of approximately 220%, with gross profits rising from 106 million to 340 million over the same period.

This data highlights Vertex's aggressive expansion and market penetration, outpacing Jazz in terms of growth rate. However, Jazz's consistent upward trend reflects a stable and sustainable business model. As the pharmaceutical industry continues to evolve, these companies' financial trajectories offer valuable insights into their strategic directions and market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025